Verve Therapeutics

NEWS
A brief rundown of the biopharmas that brought in the cash the past week.
Sizable venture rounds from cardiac gene-editing company Verve Therapeutics and the retooled fusion protein maker Vera Therapeutics will push their lead therapies into and through the clinic over the next two years.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
AWARDS
  • NextGen Class of 2020
JOBS
IN THE PRESS